Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanesepatients with dyslipidemia

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 577-583

  Tanaka, Nobuaki ^a   Ishida, Tatsuro ^a   Nagao, Manabu ^a   Mori, Takeshige ^a   Monguchi, Tomoko ^a   Sasaki, Maki ^a   Mori, Kenta ^a   Kondo, Kensuke ^a   Nakajima, Hideto ^a   Honjo, Tomoyuki ^a   Irino, Yasuhiro ^a   Toh, Ryuji ^a   Shinohara, Masakazu ^a   Hirata, Ken ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion molecule; Cholesterol efflux; Dysfunctional HDL; Eicosapentaenoic acid; High density lipoprotein; N 3 fatty acid; Paraoxonase

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG BLOOD LEVEL; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); LOW FAT DIET; MACROPHAGE; MALE; MONOCYTE; OXIDATIVE STRESS; PROTEIN EXPRESSION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84910068529     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.011     Document Type: Article

References (48)

1. Dolecek T.A. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial. Proc. Soc. Exp. Biol. Med. 1992, 200:177-182.
2. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
3. Iso H., Rexrode K.M., Stampfer M.J., Manson J.E., Colditz G.A., Speizer F.E., et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001, 285:304-312.
4. Iso H., Kobayashi M., Ishihara J., Sasaki S., Okada K., Kita Y., et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006, 113:195-202.
5. Wang C., Harris W.S., Chung M., Lichtenstein A.H., Balk E.M., Kupelnick B., et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 2006, 84:5-17.
6. Zuliani G., Galvani M., Leitersdorf E., Volpato S., Cavalieri M., Fellin R. The role of polyunsaturated fatty acids in the treatment of dyslipidemias. Curr. Pharm. Des. 2009, 15:4087-4093.
7. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
8. Saito Y., Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Ishikawa Y., et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135-140.
9. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ. Res. 2004, 95:764-772.
10. Rye K.A., Barter P.J. Cardioprotective functions of HDLs. J.Lipid Res. 2014, 55:168-179.
11. Annema W., von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ. J. 2013, 77:2432-2448.
12. Huang Y., DiDonato J.A., Levison B.S., Schmitt D., Li L., Wu Y., et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 2014, 20:193-203.
13. Soumyarani V.S., Javakumari N. Oxidized HDL induces cytotoxic effects: implications for atherogenic mechanism. J.Biochem. Mol. Toxicol. 2014, (in press). 10.1002/jbt.21588.
14. 2O/sucrose or in KBr. J.Lipid Res. 2008, 49:481-490.
15. Hara T., Ishida T., Kojima Y., Tanaka H., Yasuda T., Shinohara M., et al. Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both invitro and invivo. J.Lipid Res. 2011, 52:57-67.
16. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., et al. Oral D-4F causes formation of pre-b high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E -null mice. Circulation 2004, 109:3215-3220.
17. Miyamoto-Sasaki M., Yasuda T., Monguchi T., Nakajima H., Mori K., Toh R., et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J.Atheroscler. Thromb. 2013, 20:708-716.
18. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., et al. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation 2003, 107:2775-2779.
19. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J.Clin. Invest. 1995, 96:2758-2767.
20. Pan B., Ma Y., Ren H., He Y., Wang Y., Lv X., et al. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-B1 expression. PLoS One 2012, 7:e48530.
21. Xu S., Liu Z., Liu P. HDL cholesterol in cardiovascular disease: the good, the bad, and the ugly?. Int. J. Cardiol. 2013, 168:3157-3159.
22. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. Amajor role for VCAM-1, but not ICAM-1, in early atherosclerosis. J.Clin. Invest 2001, 107:1255-1262.
23. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J.Clin. Invest. 2007, 117:746-756.
24. La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1988, 43:227-229.
25. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
26. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-253.
27. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J.Clin. Invest. 1995, 96:2882-2891.
28. Aviram M., Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr. Opin. Lipidol. 2013, 24:339-344.
29. Inoue M., Suehiro T., Nakamura T., Ikeda Y., Kumon Y., Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000, 49:1400-1405.
30. Haraguchi Y., Toh R., Hasokawa M., Nakajima H., Honjo T., Otsui K., et al. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis 2014, 234:288-294.
31. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
32. Granér M., James R.W., Kahri J., Nieminen M.S., Syvänne M., Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J.Am. Coll. Cardiol. 2006, 47:2429-2435.
33. Burillo E., Mateo-Gallego R., Cenarro A., Fiddyment S., Bea A.M., Jorge I., et al. Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipids Health Dis. 2012, 11:116.
34. Calabresi L., Villa B., Canavesi M., Sirtori C.R., James R.W., Bernini F., et al. An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 2004, 53:153-158.
35. Hirafuji M., Machida T., Tsunoda M., Miyamoto A., Minami M. Docosahexaenoic acid potentiates interleukin-1ß induction of nitric oxide synthase through mechanism involving p44/42 MAPK activation in rat vascular smooth muscle cells. Br. J. Pharmacol. 2002, 136:613-619.
36. Arii K., Suehiro T., Ota K., Ikeda Y., Kumon Y., Osaki F., et al. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 2009, 202:439-445.
37. Mineo C., Shaul P.W. PON-dering differences in HDL function in coronary artery disease. J.Clin. Invest. 2011, 121:2545-2548.
38. Hu Y.W., Ma X., Li X.X., Liu X.H., Xiao J., Mo Z.C., et al. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived from cells. Atherosclerosis 2009, 204:35-43.
39. Berrougui H., Loued S., Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Radic. Biol. Med. 2012, 52:1372-1381.
40. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 2004, 37:1304-1316.
41. Kasbi Chadli F., Nazih H., Krempf M., Nguyen P., Ouguerram K. Omega 3 fatty acids promote macrophage reverse cholesterol transport in Hamster fed high fat diet. PLoS One 2013, 8:e61109.
42. Yamada H., Yoshida M., Nakano Y., Suganami T., Satoh N., Mita T., et al. Invivo and invitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2173-2179.
43. Toth P.P. Activation of intracellular signaling systems by high-density lipoproteins. J.Clin. Lipidol. 2010, 4:376-381.
44. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J.Lipid Res. 1999, 40:345-353.
45. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J.Lipid Res. 2000, 41:1261-1267.
46. Bays H.E., Ballantyne C.M., Braeckman R.A., Stirtan W.G., Soni P.N. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am. J. Cardiovasc Drugs 2013, 13:37-46.
47. Satoh N., Shimatsu A., Kotani K., Sakane N., Yamada K., Suganami T., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007, 30:144-146.
48. Roncaglioni M.C., Tombesi M., Avanzini F., Barlera S., Caimi V., Longoni P., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N.Engl. J. Med. 2013, 368:1800-1808.